CTLA4 and neoplasm: The selective targeting of oncogenic signaling molecules and the tumor immune microenvironment molecules (i.e., PD1/PD-L1/cytotoxic T lymphocyte associated antigen-4, CTLA-4/NKp-46/CD16/CD28/CD80/IL-2/IL-6) were evaluated.